Undisclosed SIK2 inhibitor / Nimbus Therap - LARVOL DELTA

Selective SIK2 inhibition suppresses intestinal inflammation and promotes mucosal healing in models of colitis (ECCO-IBD 2026) - "Moreover, transcriptome analysis of colon tissue samples from SIK2-inhibitor treated mice confirmed the attenuation of intestinal inflammation and upregulation of mucosal healing pathways by selective SIK2 inhibition. Conclusion Our first-in-class highly selective small molecule SIK2 kinase inhibitors represent a unique mechanism of downregulating intestinal inflammation and upregulating mucosal healing, offering a novel oral therapeutic approach for IBD."

IO biomarker • Immunology • Inflammation • Inflammatory Bowel Disease • IL10 • IL12A • IL1B • IL1R1 • IL6 • LCN2 • MUC2 • OCLN • SIK1 • TJP1 • TNFA

Nimbus Therapeutics to Present Preclinical and Translational Data on Novel SIK2 Inhibitors at 21st Congress of European Crohn’s and Colitis Organisation (ECCO) (Businesswire) - "'We look forward to advancing our novel SIK2 program toward first-in-human studies for inflammatory and autoimmune diseases in the months ahead.'"

First-in-human • New trial • Preclinical • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis